About

Médicament Québec is a coordinated initiative to support the development of innovative units dedicated to drug discovery, supply and production in Quebec and to revitalize the province’s pharmaceutical industry. Initially spurred by the need to strengthen the local supply chain, Médicament Québec brings together leading thinkers and infrastructure from universities, colleges and generic and innovative drug companies.

Find out more

Pillars

Médicament Québec provides funding for activities that, directly or indirectly, lead to the creation or the strengthening of the local pharmaceutical supply chains.

The term “pharmaceutical” is used to describe medicinal substances used to treat or prevent illnesses or specific symptoms, or to establish medical diagnoses. The products under Médicament Québec’s scope may therefore include small molecules, vaccines, antibodies, active ingredients, pharmacological agents, vectorization agents, RNAs or other compounds that meet this definition.

Activities that qualify for funding will :

  • Provide infrastructure – These activities aim to set up organizations, networks or tools that foster synergy and the development of Quebec’s pharmaceutical industry. They demonstrate significant potential for development and spin-off benefits.
  • Encourage collaboration – These activities bring together experts and stakeholders from various disciplines to collaborate on shared projects.

The activities support three strategic pillars:

Two cross-sector components

There are two cross-sector components that reinforce the 3 pillars:

  • Digital intelligence (artificial intelligence and operational research)
  • Training in university, college and corporate environments

News

A platform led by Professor Jörg Fritz of McGill University to stimulate the discovery and development of new RNA vaccines. 

Vaccines are essential for preventing infections and represent a cornerstone of strategies aimed at preparing for future epidemics and pandemics. The development of new RNA vaccines against emerging pathogens relies on the rapid identification of antigenic targets capable of eliciting effective protection against infection. However, this crucial step is often limited by the lack of efficient screening tools. Moreover, there is a need for a preclinical platform to evaluate new formulations and the effectiveness of RNA vaccines. 

Read More

Optimization and Scale-Up of RNA Therapeutics Through Next-Generation Manufacturing

RNA-based therapies and vaccines represent a versatile and preferred approach to addressing several major public health challenges. However, their production requires RNA to be encapsulated, stabilized, and delivered to the body using nanosuspensions complex structures that must be custom-formulated depending on the targeted organ or cells. This level of customization presents a significant challenge for large-scale production.

Read More

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

Read More

Collaborators

Under the leadership of the Université de Montréal, Médicament Québec aims to rally research groups, academic institutions and private companies around a common goal: revitalizing Québec’s pharmaceutical industry and increasing the province’s independence in the discovery, development and production of active ingredients used to make essential drugs and treatments. In doing so, Médicament Québec hopes to prevent future supply shortages.

See all collaborators

Contact us

Logo Médicament Québec

Address : 950, Av. Beaumont, suite 201
Montréal, QC, H3N 1V5
Canada